Agent that retards transformation of hormone-dependent cancer to non-hormone-dependent cancer

A method of retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer in a mammal in need thereof, comprising administering to said mammal:

• (i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH—C2H5 (SEQ ID NO.:
• 2) or a salt thereof and cyproterone acetate, in combination with
• (ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase activity;
• wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.

A method of treating cancer in a mammal in need thereof by retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer, comprising administering

• (i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH—C2H5 (SEQ ID NO.:
• 2) or a salt thereof, and cyproterone acetate in combination with
• (ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase activity;
• wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.

A method of suppressing the metastasis or recurrence of a cancer by retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer, in a mammal in need thereof, comprising administering

• (i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro NH—C2H5 (SEQ ID NO.:
• 2) or a salt thereof, and cyproterone acetate in combination with
• (ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase activity;
• wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.